Fig. 4

LncRNA RERE-AS1 mediates malignant phenotype and regulates the anti-tumor activity of Ribociclib in BC via the MEK/ERK signaling pathway. A Transcriptome sequencing was conducted on control and RERE-AS1 stably overexpressed cell lines, with heatmaps and volcano plots showing the differential gene expression between the two groups. B GSEA of differentially expressed genes to investigate potential signaling pathways involving RERE-AS1. C Western blot experiments confirmed the effect of RERE-AS1 overexpression on the phosphorylation levels of MEK/ERK, and the reversal of this effect by the MAPK signaling pathway activator C16-PAF. D–F CCK-8, colony formation, and EdU assays verified that the tumor proliferation suppression mediated by overexpressed RERE-AS1 could be reversed by the MAPK pathway activator C16-PAF. G–H Scratch healing and Transwell assays revealed that C16-PAF could reverse the effects on tumor invasion and migration regulated by overexpressed RERE-AS1. *p < 0.05, ***p < 0.001, ****p < 0.0001